glp 1 agonists tirzepatide Understand GLP-1/GIP Dual Agonist and Its Effect on Current Weight Loss Therapy TrimRX | GLP-1 vs GIP:

Ozempic: the truth about new weight-loss drugs Wegovy study finds weight-loss drug sharply cuts heart attacks, strokes and cardiac deaths What to do about fake weight-loss drugs and compounded versions Nutrition is vital when taking GLP-1 weight-loss drugs

Nauck and the other, anonymous reviewer(s) for their contribution to the peer review of this work

Novo Nordisk also launched an oral tablet form of Wegovy in 2025, making it the first oral GLP-1 approved for weight loss

Results After exclusions and propensity score trimming, the cohort consisted of 145 410 patients who started GLP1 receptor agonist treatment and 291 667 patients who started DPP4 inhibitor treatment (fig 1)

Close your mouth but keep your tongue relaxed and slightly elevated